Narcolepsy Type 1 Clinical Trial
— AMAZEOfficial title:
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of NLS-2 (Mazindol Extended-Release) Tablets in the Treatment of Narcolepsy Type 1
Verified date | May 2024 |
Source | NLS Pharmaceutics |
Contact | Jeff Bernier |
Phone | 617-905-2282 |
amaze[@]nls-pharma.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical trial is to see how NLS-2 (mazindol extended-release) works on symptoms of narcolepsy, including cataplexy and excessive daytime sleepiness. Approximately 48 participants will take part in the study across the United States. The study treatment (NLS-2 or placebo) will be administered for 8 weeks. After this treatment period, the participant may have the option to participate in a separate long-term extension study during which all participants will be treated with NLS-2.
Status | Not yet recruiting |
Enrollment | 48 |
Est. completion date | July 30, 2025 |
Est. primary completion date | July 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: - Adults = 18 years of age at the time of signing the informed consent. - Documented primary diagnosis of Narcolepsy Type 1 (NT1) according to the International Classification of Sleep Disorders-Third Edition (ICSD-3) criteria. - Willing and able to safely discontinue all prohibited medications, including medications for the treatment of narcolepsy. - Body Mass Index (BMI) within the range of 18 - 40 kg/m2 (inclusive). Key Exclusion Criteria: - Any other (besides narcolepsy) clinically relevant medical, behavioral, or psychiatric disorder that is associated with excessive daytime sleepiness or cataplexy. - History of myocardial infarction or significant cardiovascular disease, structural cardiac abnormalities, cardiomyopathy, congestive heart failure, cardiac arrhythmias, coronary artery disease, cerebrovascular disease (transient ischemic attack or stroke), or any other significant cardiac problem. - History of long QT Syndrome or Torsades de Pointes, or an immediate family history of sudden cardiac death. - History of pulmonary hypertension and/or valvulopathy. - History of epilepsy, convulsions, or seizures (excluding early childhood febrile seizures). - Significant history of head injury or head trauma. - Recent or active suicidal ideation or behavior - Current, or within the past year, diagnosis of substance abuse or dependence disorder (SUD) including alcohol abuse. - Narrow-angle glaucoma. - Severe renal or hepatic insufficiency. - Occupation that requires variable or nighttime shift work. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
NLS Pharmaceutics |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of cataplexy episodes at Week 8 | Cataplexy episodes is a clinical outcome measure that assesses the frequency of cataplexy episodes. | 8 weeks | |
Secondary | Patient Reported Outcomes Measurement Information System-Sleep Related Impairment (PROMIS-SRI): change from baseline | The Patient Reported Outcomes Measurement Information System-Sleep Related Impairment (PROMIS-SRI) scale consists of 8 items to evaluate daytime consequences of functioning on a 5-point Likert scale ranging from 1 to 5. The PROMIS-SRI measures self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. Each question has five response options ranging in value from 1 to 5. To find the total raw score with all questions answered, sum the values of the response to each question and total score ranges from 8 to 40. Higher scores indicates greater sleep impairment. | 8 weeks | |
Secondary | Patient Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD): change from baseline | The Patient Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) consists of a static 8-item questionnaire. Using a recall period of the past 7 days, it assesses the concepts of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items) and worrying about sleep (1 item). Each question has 5 response options ranging in value from 1 to 5. To find the total raw score with all questions answered, sum the values of the response to each question and a total score ranges from 8 to 40. Lower scores indicate less sleep disturbance. Negative changes in scores indicate improvement. | 8 weeks | |
Secondary | Epworth Sleepiness Scale (ESS): change from baseline | The Epworth Sleepiness Scale (ESS) is a patient-reported outcome measure that assesses daytime sleepiness. It asks the participant to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep in 8 different situations or activities that are commonly met in daily life. The total ESS score, ranging from 0 to 24, is the sum of 8 item scores, with higher scores indicating greater daytime sleepiness. | 8 weeks | |
Secondary | Patient Global Impression of Severity (PGI-S): change from baseline | The Patient Global Impression of Severity (PGI-S) is a patient-reported outcome measure that assesses the participant's perception of the severity of their illness. The participant rates their condition on a point scale, from "no symptoms" to "extremely severe." | 8 weeks | |
Secondary | Clinician Global Impression of Severity (CGI-S): change from baseline | The Clinical Global Impressions of Severity (CGI-S) is a clinician-rated outcome measure that assesses the clinician's impression of the participant's current illness severity. The clinician rates the severity of the participant's condition on a point scale, from "normal, not at all ill" to "among the most extremely ill patients". | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05983731 -
A Pilot Observational Study to Assess the Ability of Continuous 'Home' EEG to Accurately Diagnose Narcolepsy and Demonstrate Response to Treatment
|
||
Suspended |
NCT04419792 -
'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'
|
||
Completed |
NCT05375890 -
Clinical and Neurophysiological Characteristics of Narcolepsy
|
||
Not yet recruiting |
NCT06292598 -
Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population
|
||
Recruiting |
NCT06358950 -
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
|
Phase 2 | |
Not yet recruiting |
NCT06457945 -
Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions
|
N/A | |
Not yet recruiting |
NCT06383806 -
Decreasing Nightmares in Adults With Narcolepsy
|
N/A | |
Completed |
NCT05687903 -
A Study of TAK-861 in Participants With Narcolepsy Type 1
|
Phase 2 | |
Recruiting |
NCT05967832 -
Contribution of 7 Tesla MRI of the Hypothalamus in the Diagnosis of Type 1 Narcolepsy
|
N/A | |
Completed |
NCT05709873 -
Narcolepsy Nightmare Study
|
N/A | |
Recruiting |
NCT04483310 -
Meditation-Relaxation (MR Therapy) for Sleep Paralysis.
|
N/A | |
Completed |
NCT04445129 -
Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants
|
||
Completed |
NCT05460052 -
Evaluation of the Effectiveness of a Physical Activity Program on the Severity of Narcolepsy
|
||
Completed |
NCT05314556 -
Group Psychotherapy in Narcolepsy Type 1
|
N/A | |
Recruiting |
NCT05816382 -
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
|
Phase 2/Phase 3 | |
Recruiting |
NCT06336057 -
Mentalizating in Adults Suffering From Narcolepsy Type 1.
|
||
Recruiting |
NCT06251063 -
Improving Social Relationships for Adolescents With Central Disorders of Hypersomnolence
|
N/A | |
Completed |
NCT06241911 -
Transcutaneous Auricular Vagus Nerve Stimulation in Patients With Narcolepsy Type 1
|
N/A |